Tamiflu and Risk Of Neuropsychiatric Adverse Reactions

Oseltamivir (Tamiflu), is an anti-viral drug, in a class of medications called neuraminidase inhibitors. It is used to treat some types of influenza infection and was also used during the H1N1 pandemia, between 1 October 2009 and 31 January 2010. It is currently being studied, in combination with other anti-retroviral drugs, as a potential treatment for COVID-19. It was reported that an elderly Chinese woman had made a complete recovery after suffering from severe COVID-19-related pneumonia. (Currently, there are no FDA approved treatments for COVID-19)

A cohort study1 conducted in a tertiary care pediatric hospital during the H1N1 pandemia, evaluated children, newborn to 18 year-old patients with a flu-like illness. The observations suggested a potential influence of ABCB1 polymorphisms in oseltamivir-related Neuropsychiatric Adverse Events (NPAE), maybe as a result of an enhanced permeability of the blood-brain barrier to oseltamivir

Related to:
oseltamivir, lopinavir/ritonavir, Kaletra, covid-19